Lantheus (NASDAQ:LNTH) will present new radiopharmaceutical data at the 2026 ASCO Annual Meeting, held May 29–June 2, 2026 in Chicago.
Presentations include a Phase 1/2 study of LNTH-2403 in relapsed/refractory osteosarcoma and a publication-only abstract on real-world use of piflufolastat F 18 in early-stage prostate cancer.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – LNTH
-0.26%
-0.26%Session close to close
In the May 19 session, LNTH declined 0.26%, reflecting a mild negative market reaction.
This announcement highlights Lantheus’ continued clinical and real-world evidence work, with LNTH-24...
Analysis
This announcement highlights Lantheus’ continued clinical and real-world evidence work, with LNTH-2403 early-phase sarcoma data and piflufolastat F 18 use in early-stage prostate cancer featured at ASCO 2026. Against a backdrop of recent FDA approvals and solid financial results, investors may watch for safety, dosimetry, and activity signals from the phase 1/2 trial, as well as evolving practice patterns from the real-world imaging abstract.
Key Figures
ASCO meeting dates:May 29 – June 2, 2026LNTH-2403 trial phase:Phase 1/2Poster date:Monday, June 1+2 more
FDA tentative approval for PNT2003, radioequivalent to LUTATHERA.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news with clear regulatory wins and strong earnings (e.g., FDA approvals, Q1 beat) has generally been followed by positive price reactions.
Recent Company History
Over the last few months, Lantheus reported strong Q1 2026 results with revenue of $377.3M, GAAP EPS of $1.80, and reaffirmed $1.4B–$1.45B 2026 revenue guidance, which was followed by a 5.63% gain. FDA approval of PYLARIFY TruVu and tentative approval of PNT2003 also saw positive reactions of 10.27% and 1.86%, respectively. Today’s ASCO presentation announcement fits into an ongoing stream of clinical and diagnostic developments.
Key Terms
phase 1/2, multi-center, open-label, pharmacokinetics, +4 more
8 terms
phase 1/2medical
"A phase 1/2, multi-center, open-label study to evaluate the safety..."
Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.
multi-centermedical
"A phase 1/2, multi-center, open-label study to evaluate the safety..."
Multi-center describes a study, clinical trial, or project carried out at several separate hospitals, clinics, or research sites rather than at a single location. For investors, multi-center work generally means results are gathered from a broader set of patients and conditions, making findings more reliable and faster to enroll, but also more costly and complex to coordinate—like testing a product in many stores to see how it performs across different neighborhoods.
open-labelmedical
"A phase 1/2, multi-center, open-label study to evaluate the safety..."
Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.
pharmacokineticsmedical
"...to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry..."
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
radiation dosimetrymedical
"...tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity..."
Radiation dosimetry is the measurement and calculation of the amount of ionizing radiation absorbed by people, biological tissues, or materials. It matters to investors because accurate dosimetry determines safety, regulatory approval, product labeling and liability, and the effectiveness of medical treatments or industrial processes—much like measuring how long you can safely stay in the sun to avoid a burn, it helps companies manage risk, costs, and marketability.
anti-neoplasticmedical
"...radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403..."
Anti-neoplastic describes drugs or treatments designed to stop, shrink, or slow the growth of tumors and cancer cells; think of them like a targeted weed killer for abnormal cell growth. For investors, anti-neoplastic therapies matter because their clinical trial results, regulatory approvals, patent life and safety profiles determine market size, pricing power and commercial risk, directly affecting a biotech or pharmaceutical company's value and future revenue potential.
monoclonal antibodymedical
"...177lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma."
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
relapsed/refractorymedical
"...monoclonal antibody, in patients with relapsed/refractory osteosarcoma."
Relapsed/refractory describes a disease, usually cancer, that has returned after treatment (relapsed) or that did not respond to initial therapy (refractory). For investors this signals a high medical need and a defined patient group for new treatments — like a market of cars that won’t start with a standard key — which can affect drug development priorities, trial designs, potential pricing and commercial opportunity.
BEDFORD, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago, IL.
Presentation details are as follows:
Date & Time: Monday, June 1 Session Type: Poster
Session Title: Sarcoma Poster Number: 376b
Title: A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403, a LRRC15-targeted 177lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma.
Presenter: Noah Federman, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA
Session Type: Publication Only
Session Title: Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile Title: Real-world use of piflufolastat F 18 and imaging-associated treatment patterns in early-stage prostate cancer.
First Author: Emma Billmyer, The Analysis Group, Boston, MA
Abstract Number: e17126
About Lantheus Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Contacts:
Lantheus Mark Kinarney Vice President, Investor Relations 978-671-8842 ir@lantheus.com
What data will Lantheus (NASDAQ:LNTH) present at the 2026 ASCO Annual Meeting?
Lantheus will present data on LNTH-2403 in osteosarcoma and real-world piflufolastat F 18 use in early-stage prostate cancer. According to Lantheus, these will appear as a poster and a publication-only abstract at ASCO 2026.
When and where is Lantheus presenting LNTH-2403 osteosarcoma data at ASCO 2026?
Lantheus LNTH-2403 osteosarcoma data will be presented in a poster session on Monday, June 1, 2026, at ASCO in Chicago. According to Lantheus, the sarcoma poster is numbered 376b and reports Phase 1/2 safety and activity results.
What is the focus of Lantheus LNTH-2403 Phase 1/2 trial being featured at ASCO 2026?
The LNTH-2403 Phase 1/2 trial evaluates safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity in relapsed or refractory osteosarcoma. According to Lantheus, LNTH-2403 is an LRRC15-targeted 177lutetium-labeled monoclonal antibody studied in a multi-center, open-label design.
What will Lantheus present about piflufolastat F 18 in early-stage prostate cancer at ASCO 2026?
Lantheus will feature a publication-only abstract on real-world use of piflufolastat F 18 and imaging-associated treatment patterns in early-stage prostate cancer. According to Lantheus, the abstract is titled “Real-world use of piflufolastat F 18” with abstract number e17126.
